Pekin Hardy Strauss’s AbbVie ABBV Stock Holding History

Pekin Hardy Strauss’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.22M	Sell	28,681 -621	-2%	-$134K	0.64%	33
2026 Q1	$6.37M	Sell	29,302 -1,112	-4%	-$247K	0.67%	41
2025 Q4	$6.95M	Sell	30,414 -604	-2%	-$138K	0.64%	38
2025 Q3	$7.18M	Sell	31,018 -577	-2%	-$117K	0.72%	34
2025 Q2	$5.86M	Sell	31,595 -273	-0.9%	-$50.7K	0.67%	41
2025 Q1	$6.68M	Sell	31,868 -899	-3%	-$175K	0.81%	31
2024 Q4	$5.82M	Sell	32,767 -1,824	-5%	-$335K	0.74%	36
2024 Q3	$6.83M	Sell	34,591 -344	-1%	-$64.2K	0.87%	26
2024 Q2	$5.99M	Sell	34,935 -298	-0.8%	-$49.4K	0.82%	28
2024 Q1	$6.42M	Sell	35,233 -297	-0.8%	-$51.2K	0.88%	29
2023 Q4	$5.51M	Buy	35,530 +354	+1%	+$51.6K	0.77%	37
2023 Q3	$5.24M	Sell	35,176 -527	-1%	-$77.4K	0.83%	36
2023 Q2	$4.81M	Sell	35,703 -1,318	-4%	-$193K	0.53%	40
2023 Q1	$5.9M	Sell	37,021 -360	-1%	-$55K	0.79%	29
2022 Q4	$6.04M	Sell	37,381 -356	-0.9%	-$54.6K	0.83%	28
2022 Q3	$5.07M	Sell	37,737 -272	-0.7%	-$39K	0.81%	34
2022 Q2	$5.82M	Buy	38,009 +203	+0.5%	+$31K	0.82%	28
2022 Q1	$6.13M	Sell	37,806 -1,356	-3%	-$197K	0.76%	28
2021 Q4	$5.3M	Buy	39,162 +39	+0.1%	+$4.61K	0.72%	36
2021 Q3	$4.22M	Sell	39,123 -362	-0.9%	-$41.4K	0.6%	43
2021 Q2	$4.45M	Sell	39,485 -6	-0%	-$676	0.62%	45
2021 Q1	$4.27M	Sell	39,491 -168	-0.4%	-$18K	0.67%	40
2020 Q4	$4.25M	Buy	39,659 +1,765	+5%	+$170K	0.74%	34
2020 Q3	$3.32M	Buy	37,894 +338	+0.9%	+$31.8K	0.68%	37
2020 Q2	$3.69M	Buy	37,556 +1,614	+4%	+$142K	0.81%	34
2020 Q1	$2.74M	Sell	35,942 -2,327	-6%	-$198K	0.62%	40
2019 Q4	$3.39M	Buy	38,269 +1,289	+3%	+$107K	0.56%	45
2019 Q3	$2.8M	Sell	36,980 -2,016	-5%	-$138K	0.54%	46
2019 Q2	$2.84M	Buy	38,996 +3,045	+8%	+$239K	0.56%	44
2019 Q1	$2.9M	Buy	35,951 +203	+0.6%	+$16.6K	0.23%	45
2018 Q4	$3.3M	Sell	35,748 -448	-1%	-$39.4K	0.57%	40
2018 Q3	$3.42M	Sell	36,196 -1,166	-3%	-$111K	0.59%	45
2018 Q2	$3.46M	Sell	37,362 -1,222	-3%	-$119K	0.66%	43
2018 Q1	$3.65M	Sell	38,584 -11,939	-24%	-$1.31M	0.66%	44
2017 Q4	$4.89M	Sell	50,523 -1,648	-3%	-$155K	0.89%	32
2017 Q3	$4.64M	Sell	52,171 -712	-1%	-$54.2K	0.87%	35
2017 Q2	$3.83M	Sell	52,883 -1,072	-2%	-$72.1K	0.6%	38
2017 Q1	$3.52M	Sell	53,955 -475	-0.9%	-$29.9K	0.69%	37
2016 Q4	$3.41M	Buy	54,430 +1,270	+2%	+$77.5K	0.3%	38
2016 Q3	$3.35M	Sell	53,160 -71	-0.1%	-$4.6K	0.57%	40
2016 Q2	$3.3M	Sell	53,231 -292	-0.5%	-$17.8K	0.72%	37
2016 Q1	$3.06M	Buy	53,523 +2,618	+5%	+$146K	0.71%	36
2015 Q4	$3.02M	Buy	50,905 +13,488	+36%	+$777K	0.69%	39
2015 Q3	$2.04M	Buy	37,417 +2,088	+6%	+$136K	0.46%	43
2015 Q2	$2.37M	Buy	35,329 +13,765	+64%	+$899K	0.46%	43
2015 Q1	$1.26M	Sell	21,564 -33,129	-61%	-$2M	0.23%	62
2014 Q4	$3.58M	Buy	54,693 +34,022	+165%	+$2.14M	0.53%	40
2014 Q3	$1.19M	Hold	20,671	–	–	0.2%	56
2014 Q2	$1.17M	Hold	20,671	–	–	0.18%	56
2014 Q1	$1.06M	Sell	20,671 -598	-3%	-$30.2K	0.17%	55
2013 Q4	$1.12M	Sell	21,269 -1,500	-7%	-$73.7K	0.17%	57
2013 Q3	$1.02M	Hold	22,769	–	–	0.16%	56
2013 Q2	$941K	Buy	+22,769	New	+$996K	0.16%	59

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Pekin Hardy Strauss's ABBV Position: Q2 2026 in Review

Pekin Hardy Strauss reduced its AbbVie (ABBV) stake by 2.1% in Q2 2026, selling an estimated $134K and leaving 28,681 shares worth $7.22M. The position accounts for 0.64% of the portfolio, ranked #33.

Pekin Hardy Strauss first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Pekin Hardy Strauss held 28,681 shares of AbbVie worth $7.22M as of Q2 2026.
Pekin Hardy Strauss sold 621 AbbVie shares in Q2 2026, an estimated $134K.
AbbVie made up 0.64% of Pekin Hardy Strauss's portfolio in Q2 2026, its #33 holding.
Pekin Hardy Strauss first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Pekin Hardy Strauss's 13F filing for Q2 2026, filed 30 Jul 2026.